Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions

Human Pathology

Volumn 40, Issue 4, 2009, Pages 527-537

  Slipicevic, Ana ^a   Øy, Geir Frode ^a   Askildt, Inger Cecilie ^a   Holth, Arild ^a   Hellesylt, Ellen ^a   Flørenes, Vivi Ann ^a   Davidson, Ben ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Carcinoma; Effusions; Insulin like growth factor; Mesothelioma; Survival

Indexed keywords

SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DIAGNOSTIC VALUE; EFFUSION; ENDOMETRIUM CARCINOMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROINTESTINAL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CARCINOMA; MALIGNANT MESOTHELIOMA; OVARY CARCINOMA; OVERALL SURVIVAL; PERITONEUM MESOTHELIOMA; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN METHYLATION; UROGENITAL TRACT CANCER; UTERINE CERVIX CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ASCITIC FLUID; CARCINOMA; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR II; KAPLAN-MEIERS ESTIMATE; MESOTHELIOMA; MIDDLE AGED; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 62049086022     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2008.10.003     Document Type: Article

References (29)

1. Bedrossian C.W.M. Malignant effusions: a multimodal approach to cytologic diagnosis (1994), Igaku-Shoin, New York (NY)
2. Bonnefoi H., A'Hern R.P., Fisher C., et al. Natural history of stage IV epithelial ovarian cancer. J Clin Oncol 17 (1999) 765-775
3. Banerjee A.K., Willetts I., Robertson J.F., and Blamey R.W. Pleural effusion in breast cancer: a review of the Nottingham experience. Eur J Surg Oncol 20 (1994) 33-36
4. Sachdev D., and Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 6 (2007) 1-12
5. Guvakova M.A. Insulin-like growth factors control cell migration in health and disease. Int J Biochem Cell Biol 39 (2007) 890-909
6. Denley A., Cosgrove L.J., Booker G.W., Wallace J.C., and Forbes B.E. Molecular interactions of the IGF system. Cytokine Growth Factor Rev 16 (2005) 421-439
7. Bach L.A., Headey S.J., and Norton R.S. IGF-binding proteins-the pieces are falling into place. Trends Endocrinol Metab 16 (2005) 228-234
8. Firth S.M., and Baxter R.C. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23 (2002) 824-854
9. Davidson B., Zhang Z., Kleinberg L., et al. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma. Clin Cancer Res 12 (2006) 5944-5950
10. Davidson B., Nielsen S., Christensen J., et al. The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol 25 (2001) 1405-1412
11. Sambrook J., and Russell D.V. Molecular cloning. A laboratory manual. 3rd ed. (2001), Cold Spring Harbor Laboratory Press, Cold Spring Harbor (NY) Section 6:4
12. Tomii K., Tsukuda K., Toyooka S., et al. Aberrant promoter methylation of insulin-like growth factor binding protein-3 gene in human cancers. Int J Cancer 120 (2007) 566-573
13. Davidson B. Malignant effusions: from diagnosis to biology. Diagn Cytopathol 31 (2004) 246-254
14. Davidson B. The biological characteristics of cancers involving the serosal cavities. Crit Rev Oncog 13 (2007) 189-227
15. Fetsch P.A., and Abati A. Immunocytochemistry in effusion cytology: a contemporary review. Cancer 93 (2001) 293-308
16. Ordonez N.G. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Am J Surg Pathol 22 (1998) 1203-1214
17. Ordonez N.G. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 27 (2003) 1418-1428
18. Bassarova A.V., Nesland J.M., and Davidson B. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions. Am J Surg Pathol 30 (2006) 878-882
19. Davidson B., Baekelandt M., and Shih I.e.M. MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells. Diagn Cytopathol 35 (2007) 756-760
20. Kleinberg L., Holth A., Fridman E., Schwartz I., Shih I.e.M., and Davidson B. The diagnostic role of claudins in serous effusions. Am J Clin Pathol 127 (2007) 928-937
21. Davidson B., Skrede M., Silins I., Shih I.e.M., Trope' C.G., and Flørenes V.A. Low molecular weight cyclin E forms differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma. Cancer 110 (2007) 1264-1271
22. Walker G., MacLeod K., Williams A.R., Cameron D.A., Smyth J.F., and Langdon S.P. Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer. Clin Cancer Res 13 (2007) 1438-1444
23. Vestey S.B., Perks C.M., Sen C., Calder C.J., Holly J.M., and Winters Z.E. Immunohistochemical expression of insulin-like growth factor binding protein-3 in invasive breast cancers and ductal carcinoma in situ: implications for clinicopathology and patient outcome. Breast Cancer Res 7 (2005) R119-R129
24. Davidson B., Risberg B., Kristensen G., et al. Detection of cancer cells in effusions from patients diagnosed with gynecological malignancies-evaluation of five epithelial markers. Virchows Arch 435 (1999) 43-49
25. Le Bouc Y., Bellocq A., Philippe C., et al. Insulin-like growth factors and their binding proteins in pleural fluid. Eur J Endocrinol 137 (1997) 467-473
26. Wiley A., Katsaros D., Fracchioli S., and Yu H. Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer. Int J Gynecol Cancer 16 (2006) 210-218
27. Katsaros D., Yu H., Levesque M.A., et al. IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival. Eur J Cancer 37 (2001) 478-485
28. Lu L., Katsaros D., Wiley A., et al. The relationship of insulin-like growth factor-II, insulin-like growth factor binding protein-3, and estrogen receptor-alpha expression to disease progression in epithelial ovarian cancer. Clin Cancer Res 12 (2006) 1208-1214
29. Sayer R.A., Lancaster J.M., Pittman J., et al. High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer. Gynecol Oncol 96 (2005) 355-361